{"filing":{"accession_number":"0000950103-26-009745","cik":"0001651625","ticker":"ACIU","company_name":"AC Immune SA","form":"6-K","filing_date":"2026-06-30","report_date":null,"primary_document":"dp249254_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1651625/000095010326009745/dp249254_6k.htm"},"events":[{"id":14898,"run_id":13282,"accession_number":"0000950103-26-009745","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"This is a clinical trial data announcement press release disclosing interim 12-month results from the Phase 1b/2 ABATE trial of ACI-24. While not traditional financial earnings, the disclosure of clinical trial progress, safety data, and dose-response results for a lead therapeutic candidate is material to investors in a clinical-stage biopharmaceutical company. The announcement also references a $12 million milestone payment from Takeda triggered by dosing in Cohort AD4, which is a material financial event. The press release format and disclosure of interim trial results align with how clinical-stage biotech companies communicate material operational and financial developments to investors.","company_name":"AC Immune SA","ticker":"ACIU","filing_date":"2026-06-30","form":"6-K","submitted_at":null,"items":[{"id":12476,"accession_number":"0000950103-26-009745","item_number":"EX-99.1","item_title":"dp249254_ex9901.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This is a clinical trial data announcement press release disclosing interim 12-month results from the Phase 1b/2 ABATE trial of ACI-24. While not traditional financial earnings, the disclosure of clinical trial progress, safety data, and dose-response results for a lead therapeutic candidate is material to investors in a clinical-stage biopharmaceutical company. The announcement also references a $12 million milestone payment from Takeda triggered by dosing in Cohort AD4, which is a material financial event. The press release format and disclosure of interim trial results align with how clinical-stage biotech companies communicate material operational and financial developments to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-30T13:04:39.537716+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12476,"accession_number":"0000950103-26-009745","item_number":"EX-99.1","item_title":"dp249254_ex9901.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This is a clinical trial data announcement press release disclosing interim 12-month results from the Phase 1b/2 ABATE trial of ACI-24. While not traditional financial earnings, the disclosure of clinical trial progress, safety data, and dose-response results for a lead therapeutic candidate is material to investors in a clinical-stage biopharmaceutical company. The announcement also references a $12 million milestone payment from Takeda triggered by dosing in Cohort AD4, which is a material financial event. The press release format and disclosure of interim trial results align with how clinical-stage biotech companies communicate material operational and financial developments to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-30T13:04:39.537716+00:00","company_name":"AC Immune SA","ticker":"ACIU","filing_date":"2026-06-30"}]}